At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 113 enrolled
Drug / intervention
CLP +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Multi-center Study Comparing CLP Versus Placebo in Heart Failure Patients With Chronic Kidney Disease
In Brief
A Phase 2 clinical trial evaluating CLP and Placebo for Heart Failure. Completed, enrolled 113 participants across 3 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine the effects of CLP on serum potassium and signs and symptoms of fluid overload in heart failure patients with chronic kidney disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesArmenia, Georgia, Moldova
CollaboratorsPharmaterra
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2010
Enrollment StartApr 2011
Primary CompletionNov 2011
TodayJul 2026
First PostedDec 23, 2010
Enrollment StartApr 1, 2011
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 15.5 years ago
Interventions
CLPdrug
Oral administration
Placebodrug
Oral administration